Delamanid is sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth. There are Common side effects which include headache, dizziness, and nausea. Other side effects include QT prolongation. Delamanid works by blocking the manufacture of mycolic acids thus destabilising the bacterial cell wall. It is in the nitroimidazole class of medications. Delamanid was approved for medical use in 2014 in Europe, Japan, and South Korea. It is on the World Health Organization's List of Essential Medicines. As of 2016 the Stop TB Partnership had an agreement to get the medication for US$1,700 per six month for use in more than 100 countries. Source: Wikipedia (en)